SISVEL
9.5.2024 11:41:30 CEST | Business Wire | Press release
A new agreement between Nordic Semiconductor and patent pool administrator Sisvel for the licensing of standard essential patents (SEPs) reading on LTE-M and NB-IoT cellular technology has been announced. The agreement creates a framework for easy and transparent access to the LTE-M and NB-IoT radio technology standards for a diverse range of IoT applications.
Specifically, the initiative provides a simple, efficient way for IoT device makers to obtain end-product licences from more than 30 patent owners holding LTE-M and NB-IoT SEPs, through Nordic as the cellular module supplier.
The agreement addresses the challenges posed by the diversity within the cellular IoT market, in which a multitude of companies - from startups to established corporations - are innovating. The wide range of significant initiatives being rolled out in areas such as smart-health, smart-energy, smart-cities and asset-tracking are currently at risk of stalling because of the lack of predictability and transparency in the access to and the cost of SEP licensing.
By offering standardised licences the agreement will reduce business uncertainty and the possibility of litigation. This will allow companies to focus on what they do best - developing new, innovative products and services for the IoT market.
"Nordic Semiconductor has always been at the forefront of wireless technology and we understand the importance of accessible and standardised licensing for the advancement of the IoT industry," comments Øyvind Birkenes, Nordic’s EVP Long Range. "We believe that this solution is a significant step towards a more efficient future for cellular IoT development."
"We are thrilled to have a unique licensing programme for cellular IoT backed by more than 30 patent owners and we believe this new agreement with Nordic addresses a critical need in the IoT ecosystem," says Sisvel CEO Mattia Fogliacco. "Our goal is to create a balanced and transparent licensing environment that supports innovation and growth for all stakeholders."
“We have worked hard with Sisvel and the SEP owners in its pool over the last year to broker this agreement because the IoT market urgently needs transparency and predictability,” says Kristian Sæther, Nordic’s Product Director – Cellular IoT. “Existing SEP licensing in the IoT space is up-in-the-air, putting countless SMEs across the globe developing wireless products in limbo. This new agreement offers efficiency and predictability to our customers. We look forward to seeing our peers and competitors recognise the importance of this work, and joining the pool solution, so that the entire cellular IoT market can operate with more predictability, and on a level playing field.”
About Sisvel
Sisvel is driven by a belief in the importance of collaboration, ingenuity and efficiency to bridge the needs of patent owners and those who wish to access their technologies. In a complex and constantly evolving marketplace, our guiding principle is to create a level playing field with the development and implementation of flexible, accessible, commercialisation solutions.
About Nordic Semiconductor
Nordic Semiconductor is a complete end-to-end wireless connectivity solutions provider, with a world-leading position in Bluetooth Low Energy, and an emerging leader in Cellular IoT, NR+, and Wi-Fi wireless technologies, Matter, Thread, Zigbee, and power management. The company’s low power wireless solutions enable millions of IoT devices to connect. Using Nordic’s innovation, its customers and partners across the globe are changing societies and lives for the better by powering smarter, safer, and more sustainable solutions. Nordic’s world-class hardware, software, and development tools are amongst the most advanced in the world, and the company deliver a complete developer experience by offering ultra-low power wireless solutions that are easy to implement, with the best possible support.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240509154129/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom